Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants receive injection of ISB 2001 as determined in Part 1.”In the company’s words, NCT05862012 on ClinicalTrials.gov
- Tested for
- Relapsed/Refractory Multiple Myeloma
- Main trialPhase 1
- “This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).”In the company’s words, NCT05862012 on ClinicalTrials.gov
Other drugs for Relapsed/Refractory Multiple Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up1
- Jul 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jul 2027 | Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026